Icon

ZYDELIG (nda205858)- (100MG,150MG)

IDELALISIB GILEAD SCIENCES INC
100MG,150MG
Yes No
2033-Sep-02 2019-Jul-23
2021-Jul-23 None
None No
Zydelig is a kinase inhibitor indicated for the treatment of patients with: • Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
0 0 0
Total Other Developers 3
Drugs with Suitability No
100MG ** ** - - -
150MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.